Inhibitory effect of D1-like and D3 dopamine receptors on norepinephrine-induced proliferation in vascular smooth muscle cells

Am J Physiol Heart Circ Physiol. 2008 Jun;294(6):H2761-8. doi: 10.1152/ajpheart.01344.2007. Epub 2008 Apr 25.

Abstract

The sympathetic nervous system plays an important role in the regulation of blood pressure. There is increasing evidence for positive and negative interactions between dopamine and adrenergic receptors; the activation of the alpha-adrenergic receptor induces vasoconstriction, whereas the activation of dopamine receptor induces vasorelaxation. We hypothesize that the D1-like receptor and/or D3 receptor also inhibit alpha1-adrenergic receptor-mediated proliferation in vascular smooth muscle cells (VSMCs). In this study, VSMC proliferation was determined by measuring [3H]thymidine incorporation, cell number, and uptake of 3-(4,5-dimethylthiazol-2-yl)-diphenyltetrazolium bromide (MTT). Norepinephrine increased VSMC number and MTT uptake, as well as [3H]thymidine incorporation via the alpha1-adrenergic receptor in aortic VSMCs from Sprague-Dawley rats. The proliferative effects of norepinephrine were attenuated by the activation of D1-like receptors or D3 receptors, although a D1-like receptor agonist, fenoldopam, and a D3 receptor agonist, PD-128907, by themselves, at low concentrations, had no effect on VSMC proliferation. Simultaneous stimulation of both D1-like and D3 receptors had an additive inhibitory effect. The inhibitory effect of D3 receptor was via protein kinase A, whereas the D1-like receptor effect was via protein kinase C-zeta. The interaction between alpha1-adrenergic and dopamine receptors, especially D1-like and D3 receptors in VSMCs, could be involved in the pathogenesis of hypertension.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adrenergic alpha-1 Receptor Agonists
  • Adrenergic alpha-Antagonists / pharmacology
  • Animals
  • Aorta / metabolism
  • Benzopyrans / pharmacology
  • Cell Proliferation* / drug effects
  • Cells, Cultured
  • Cyclic AMP-Dependent Protein Kinases / metabolism
  • Dopamine Agonists / pharmacology
  • Dose-Response Relationship, Drug
  • Fenoldopam / pharmacology
  • Molecular Chaperones / metabolism
  • Muscle, Smooth, Vascular / drug effects
  • Muscle, Smooth, Vascular / enzymology
  • Muscle, Smooth, Vascular / metabolism*
  • Myocytes, Smooth Muscle / drug effects
  • Myocytes, Smooth Muscle / enzymology
  • Myocytes, Smooth Muscle / metabolism*
  • Norepinephrine / metabolism*
  • Oxazines / pharmacology
  • Prazosin / pharmacology
  • Rats
  • Rats, Sprague-Dawley
  • Receptors, Adrenergic, alpha-1 / metabolism*
  • Receptors, Dopamine D1 / agonists
  • Receptors, Dopamine D1 / metabolism*
  • Receptors, Dopamine D2 / agonists
  • Receptors, Dopamine D2 / metabolism*

Substances

  • Adrenergic alpha-1 Receptor Agonists
  • Adrenergic alpha-Antagonists
  • Benzopyrans
  • Dopamine Agonists
  • Molecular Chaperones
  • Oxazines
  • Prkcz protein, rat
  • Receptors, Adrenergic, alpha-1
  • Receptors, Dopamine D1
  • Receptors, Dopamine D2
  • 3,4,4a,10b-tetrahydro-4-propyl-2H,5H-(1)benzopyrano(4,3-b)-1,4-oxazin-9-ol
  • Cyclic AMP-Dependent Protein Kinases
  • Fenoldopam
  • Norepinephrine
  • Prazosin